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Abstract
Background: The presence of mammary glands distinguishes mammals from other organisms. Despite significant
advances in defining the signaling pathways responsible for mammary gland development in mice, our
understanding of human mammary gland development remains rudimentary. Here, we identified a woman with
bilateral amastia, ectodermal dysplasia and unilateral renal agenesis. She was found to have a chromosomal
balanced translocation, 46,XX,t(1;20)(p34.1;q13.13). In addition to characterization of her clinical and cytogenetic
features, we successfully identified the interrupted gene and studied its consequences.
Methods: Characterization of the breakpoints was performed by molecular cytogenetic techniques. The interrupted
gene was further analyzed using quantitative real-time PCR and western blotting. Mutation analysis and high-
density SNP array were carried out in order to find a pathogenic mutation. Allele segregations were obtained by
haplotype analysis.
Results: We enabled to identify its breakpoint on chromosome 1 interrupting the protein tyrosine receptor type F
gene (PTPRF). While the patient’s mother and sisters also harbored the translocated chromosome, their non-
translocated chromosomes 1 were different from that of the patient. Although a definite pathogenic mutation on
the paternal allele could not be identified, PTPRF’s RNA and protein of the patient were significantly less than those
of her unaffected family members.
Conclusions: Although ptprf has been shown to involve in murine mammary gland development, no evidence
has incorporated PTPRF in human organ development. We, for the first time, demonstrated the possible association
of PTPRF with syndromic amastia, making it a prime candidate to investigate for its spatial and temporal roles in
human breast development.
Keywords: amastia athelia, development of breasts and nipples, ectodermal dysplasia, renal agenesis, balanced
chromosome translocation, PTPRF, LAR
Background
Excellent progress has been made in defining the signal-
ing pathways responsible for mammary gland develop-
ment in mice [1], current knowledge about human
mammary gland development is however very restricted
and requires further elucidation. This may be related to
the extreme rarity of absence of breast or amastia, with
only about 62 patients reported in the literature
(Additional file 1, Table S1). Amastia has likely been
selected against in human evolution, but its occurrence
provides an invaluable means to identify genes involved
in human breast development.
Amastia is the complete absence of breast which is the
result of complete failure of mammary ridge to develop
at about 6 weeks in utero [2]. In addition, there is a lack
of breast development during puberty whereas other
secondary sexual characters and fertility are normal [2].
Amastia can be isolated or syndromic. Syndromes asso-
ciated with the absence of breasts and nipples include
ectodermal dysplasia of the tricho-odonto-onychial type
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trophic-diabetes (AREDYLD syndrome) (MIM# 207780),
and the scalp-ear-nipple syndrome (SEN or Finlay-
Marks syndrome) (MIM# 181270). The latter is the
most common amastia-associated syndrome. Addition-
ally, renal involvement has been reported in some cases
of scalp-ear-nipple syndrome [3,4]. In familial cases of
amastia, both autosomal dominant and autosomal reces-
sive inheritances have been reported (Additional file 1,
Table S1).
Here we reported an 18-year-old female with syndro-
mic amastia who had a reciprocal balanced transloca-
tion, 46, XX, t(1;20)(p34.1;q13.13). In addition to
characterization of her clinical and cytogenetic features,
we successfully identified the interrupted gene and stu-
died its consequences.
Methods
Clinical descriptions
We identified an 18-year-old Thai woman who pre-
sented to plastic surgeons for total breast reconstruc-
tion. Menarche occurred at age 14 years and
menstruation was regular. She had been generally
healthy with normal intelligence. Height was normal
(157 cm, 50th centile). Blood pressure was 140/90
mmHg. The patient had epicanthal folds, small and cup-
shaped pinnae, absence of all four upper incisors (small,
brown and easily decayed) after extraction at age 15
years (Figure 1A), bilateral absence of breasts and nip-
ples, normal pectoralis muscles, brittle nails and normal
external genitalia. Ultrasonography and computed tomo-
graphy of the kidneys revealed absence of the left kidney
and left renal artery, yet normal right kidney and uterus
(Figure 1B). A renal function study by a post captopril
Tc-99 mMAG3 test showed normal right kidney func-
tion with no demonstrable left kidney. The patient was
the third child with an elder brother, an elder sister and
a younger sister. Her father was deceased. No other
family member was affected.
Karyotype Analysis
Peripheral blood samples from the patient and her family
members were obtained after written informed consent.
Metaphase chromosomes were obtained from phytohe-
magglutinin (PHA)-stimulated peripheral blood lympho-
cytes. G-banding was performed using standard methods.
The karyotype was at a resolution of 550 bands.
Fluorescence in situ hybridization (FISH)
Cell suspensions from the phytohemagglutinin (PHA)-
stimulated peripheral blood lymphocytes were used in
all FISH experiments. Probes mapping to the region of
the cytogenetically determined breakpoints were selected
from the Mapviewer NCBI http://www.ncbi.nlm.nih.gov/
mapview/ and obtained from the BACPAC Resources
Center (BPRC, Oakland, CA) (Additional file 1, Table
S2). BACs, PACs, or long-range PCR (10 kb each) pro-
ducts were labeled by nick translation with Spectrum
Green or Spectrum Orange according to manufacturer’s
protocols (Abbott Molecular/Vysis, Des Plains, IL).
Labeled probes were denatured and hybridized to meta-
phase spreads on the microscope slide.
Generation of FISH probes using long-range PCR
Three primer pairs were chosen from the genomic
sequence of breakpoint-spanning clone on chromosome
Figure 1 Clinical features of the proband.( A )F a c es h o w s
absence of all four upper incisors (small, brown and easily decayed)
after extraction at age 15 years, epicanthal folds, and small cup-
shaped pinnae. (B) Computerized tomography of kidneys shows
absence of the left kidney and its renal artery.
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probe was overlapped and used for subsequent FISH
analysis. We used 200 ng of plasmid DNA, 1X Ampli-
buffer C (Vivantis, Oceanside, CA), 160 mM (NH4)2SO4,
500 mM Tris-HCl,17.5 mM MgCl2 and stabilizers, 0.4
mM dNTPs, 0.4 μM of each primer and 2.5 U Perpetual
OptiTaq DNA polymerase (Vivantis, Oceanside, CA) in
a total volume of 50 μl. The PCR amplification was per-
formed as follows: initial denaturation at 95°C for 15
minutes, followed by 40 cycles of denaturation at 95°C
for 30 seconds. The annealing step was performed at
optimal annealing temperature for each specific primer
for 30 seconds. The extension was at 72°C for 11 min-
utes and the final extension was at 72°C for 10 minutes.
Analysis of repetitive elements within the breakpoint
region
We screened DNA sequences for interspersed repeats
and low complexity DNA sequences in the breakpoint
region using RepeatMasker available at http://www.
repeatmasker.org/.
Establishment of Ebstein-Barr virus immortalization of
human B-lymphocytes
We isolated Peripheral Blood Mononuclear Cells
(PBMCs) using Ficoll-Parque gradient. Peripheral blood
lymphocytes (B-lymphocytes) were immortalized by
infecting them with active Epstein Barr Virus superna-
tant [5]. Cyclosporin A was added to suppress the
growth of the T cells present in the preparation. Half of
the supernatant was replaced by fresh medium once a
week. Transformation occurred within 2 to 3 weeks
after starting the culture. The human immortalized cells
were seeded with the primary culture medium
(RPMI1640 with 20% fetal bovine serum, 100 units/ml
of penicillin-streptomycin) and were cultured in 37°C
with 5% CO2.
Quantitative Real-Time PCR
PTPRF RNA level was quantified by StepOnePlus™
Real-Time PCR Systems (Applied Biosystems, Foster
City, CA). Total RNA extracted from EBV transformed
lymphoblastoid cell lines was converted to cDNA using
the SuperScript III First-Strand Synthesis System for
RT-PCR (Invitrogen, Carlsbad, CA). PTPRF RNA levels
were studied by quantitative real-time analysis (qRT),
using two different TaqMan probes. The first one,
Hs00160858_m1 (Applied Biosystems, Foster city, CA),
spanning exons 5 and 6, is 5’ to the chromosomal
breakpoint, while the other, Hs00892984_m1 (Applied
Biosystems), spanning exons 32 and 33, is 3’ to the
breakpoint. The probes were run in triplicate in separate
tubes. Relative expression analysis was calculated in
terms of ΔΔCt normalized to GAPDH transcript levels,
using forward primer; 5’-GTGAAGGTCGGAGT-
CAACGG-3’, reverse primer; 5’-TCAATGAAGGGGT-
CATTGATGG-3’ and probe; HEX-CGCCTGGTCA
CCAGGGCTGC-BHQ1.
Western Blot Analysis
Lymphoblastoid protein was extracted using ice-cold
RIPA lysis buffer with Halt protease inhibitor cocktail
(Pierce, Roxford, IL). Protein concentration was deter-
mined using the BCA protein assay reagent (Pierce,
Roxford, IL). Western blot was performed in triplicate.
Protein extract of 100 μg was electrophoresed, trans-
ferred to PVDF membrane and incubated with 1:100
anti-PTPRF (BD Transduction Laboratory, San Jose,
CA) and 1:1000 goat anti-mouse IgG-HRP: sc-2005
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The
membrane was stripped and reprobed with 1:1000 anti-
GAPDH (Trevigen, Gaitherburgs, MD) and 1:1000 goat
anti-rabbit IgG-HRP: sc-2030 (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). PTPRF expression was nor-
m a l i z e dw i t hG A P D Ha n dc o m p a r e dw i t ht h a to fa
control.
Mutation analysis
Total RNA and genomic DNA were extracted from per-
ipheral blood using Qiagen RNA and DNA extraction
kits according to manufacturer’s instructions, respec-
tively (Qiagen, Valencia, CA). Reverse transcription was
performed using ImProm-II™ reverse transcriptase
(Promega, Madison, WI), according to the manufac-
turer’s instructions. PCR amplification of the entire cod-
ing sequence of the PTPRF gene, its promoter [6] (-654
to + 294) and cDNA amplification was performed using
set of primers and parameters (Additional file 1, Table
S4). In brief, we used 50 ng of either genomic DNA or
100 ng of cDNA, 1×PCR buffer (Promega, Madison,
WI), 1.5 mM MgCl2, 0.2 mM dNTPs, 0.2 μMo fe a c h
primer and 0.5 U Taq DNA polymerase (Promega) in a
volume of 20 μl. Amplification of the promotor
sequences of the PTPRF gene was performed in a reac-
tion mixture of 1× Qiagen PCR buffer (containing 1.5
mM MgCl2), 1× Q-Solution, 0.1 unit HotStarTaq (Qia-
gen), 200 μMd N T P s ,0 . 2μM of each primer and 50 ng
of genomic DNA. PCR products were treated with Exo-
SAP-IT (USP Corporation, Cleveland, OH) according to
the manufacturer’s recommendations, and sent for
direct sequencing (Macrogen Inc., Seoul, Korea).
Sequence data were analyzed using Sequencher (version
4.2; Gene Codes Corporation, Ann Arbor, MI).
High-density SNP genotyping array
We performed SNP array for genome wide genotyping
using Illumina Human 1 M BeadArray. SNP genotyping
was performed according to manufacturer’sp r o t o c o l s .
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cence (’x’ and ‘y’), between-sample normalized fluores-
cence (’Log R ratio’ and ‘B-allele frequency’)a n dS N P
genotype calling. We analyzed data using Bead Studio
software and PennCNV. The PennCNV package is avail-
able at http://www.openbioinformatics.org/penncnv.
Haplotype analysis
Panels 1 and 2 of the ABI Prism Linkage Mapping Set
version 2.5 (Applied Biosystems, Foster City, CA) were
amplified. These two panels consist of 31 tandem repeat
markers on chromosome 1 that define a 10 cM resolu-
tion human index map. Each panel consists of a group of
markers that were fluorescently labeled with FAM, HEX,
or NED. Amplifications were carried out as single reac-
tions in 96 well plates, according to the manufacturer’s
protocols. An additional four microsatellite markers
selected from Mapviewer, NCBI (D1S3721, D1S2645,
D1S2713, D1S3728) were used. These markers were
amplified in a 20 μl reaction mixture containing 50 ng
DNA, 0.2 μM of each primer, 0.2 mM dNTPs, 1×PCR
buffer (Fermentas Inc., Maryland), 1.5 mM MgCl2 and
0.5 U Taq DNA polymerase (Fermentas Inc., Maryland).
PCR condition was performed as follows: initial dena-
turation at 95°C for 5 minutes, followed by 35 cycles of
denaturation at 95°C for 45 seconds, annealing at 60°C
for 45 seconds, extension at 72°C for 45 minutes and a
final extension at 72°C for 10 minutes. After PCR-ampli-
fication of genomic DNA samples, amplified fragments
were resolved on an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA) together with
ROX-500 size standard (Applied Biosystems, Foster City,
CA). The resulting genotype data were analyzed using
GeneScan Analysis (Applied Biosystems, Foster City,
CA). Allele numbers were assigned for each marker
based on the size of the amplified fragment.
Results
Karyotype analysis revealed an apparently reciprocal
balanced translocation of t(1;20)(p34.1;q13.13) (Figure
2A). This similar translocation was also present in her
unaffected mother and two unaffected family sisters
Figure 2 Karyotype, FISH, and the breakpoint on chromosome 1. (A) Partial karyotype shows apparently reciprocal balanced translocation of
1p34.1 and 20q13.13. (B) Fluorescence in situ hybridization using RP5-1029K14 labeled in red with spectrum orange dUTP, shows hybridization
signals on both derivative chromosomes indicating that this probe encompasses the breakpoint. The 1p subtelomeric probe labeled with
spectrum green dUTP indicates chromosome 1. (C) Schematic presentation of the clones and genes in the 1p34.1 region, modified from the
NCBI Map Viewer http://www.ncbi.nlm.nih.gov/mapview. Three ~10 kb probes are shown in green numbered from left to right, BAC/PAC contigs
covering the 1p34.1 breakpoint are shown in purple. The orange dotted lines indicate the critical region.
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46, XY.
Performing FISH, we identified the breakpoints on
chromosomes 1 and 20 in the RP5-1029K14 and RP11-
347D21 clones, respectively. While the RP11-347D21
clone did not contain any known genes, the RP5-
1029K14 clone contained a gene, Protein Tyrosine Phos-
phatase Receptor type F (PTPRF) (MIM# 179590). We
further narrowed the critical region, using the RP5-
1029K14 clone as template and approximately 10-kb
probes produced by long range PCR. One subfragment
probe, covering intron 7 to intron 11 of the PTPRF
gene, gave a split signal (Figure 2B, C). Analysis of the
repetitive sequence elements in the vicinity of the break-
point region found Alu, MIR (Mammalian Interspersed
Repeat), LINE-L2, and ERVL-MaLRs (Endogenous Ret-
rovirus; transposable element - Mammalian apparent
LTR-Retrotransposon).
Quantitative real-time PCR analysis revealed that the
PTPRF’s RNA level of the proband was significantly
decreased (p < 0.01) compared with those of her
mother, elder sister and a control (Figure 3A, B). RNA
levels in the mother and elder sister were higher using
the 5’ probe compared with the 3’ probe. In addition,
the mother’s PTPRF RNA level, determined by the 3’
probe, was approximately half that of the control.
Western blot analysis revealed that PTPRF was nearly
absent in the proband, while her unaffected mother and
older sister had significant (p < 0.05) PTPRF protein
remaining (Figure 3C, D).
Sequencing of the gene’s entire coding regions and its
promoter revealed many polymorphisms (Additional file
1, Table S5), but no obviously pathogenic mutations. In
addition, reverse transcribed - PCR using RNA from
peripheral leukocytes yielded no aberrant splicing pat-
terns (data not shown).
Measurement of both DNA copy number and allelic
ratios by High-density SNP genotyping array showed no
evidence of deletions or duplications (Additional file 1,
Figure S1). However, microsatellite analysis showed that
the proband inherited a paternal chromosome different
from that of her sisters (Additional file 1, Figure S2).
Discussion
While studies in murine models revealed a crucial role
of ptprf in mammary gland development, there has
been no evidence of the PTPRF involvement in human
breast development. Although, somatic mutations in
the PTPRF gene have been found in many malignan-
cies including breast cancer, its germline mutations
have not been identified to cause any known human
diseases.
Figure 3 Expression studies of the PTPRF.( A )R e l a t i v e
quantification using 5’PTPRF probe (proximal to the breakpoint)
showed that the expression level in the proband was significantly
decreased compared with that in a control, the proband’s mother
and sister. (B) Relative quantification using the 3’PTPRF probe (distal
to the breakpoint) showed significantly decreased expression in the
proband. Data are presented as mean ± SEM. ** indicates P < 0.01
(independent 1-tailed t-test) using GAPDH as a control. (C) Western
blot analysis showing levels of the PTPRF protein (150 kDa) and
GAPDH (38 kDa). (D) Western blot analysis indicates nearly absent
PTPRF in the proband. Data are represented as mean ± SEM. *
indicates P < 0.05 (independent 1-taliled t-test) using GAPDH as a
control.
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breasts and nipples along with ectodermal dysplasia and
unilateral renal agenesis. Complete absence of breast is
av e r yr a r ec o n g e n i t a la n o m a l y .I tc a no c c u ra l o n eo r
with a wide range of associated features with a defect in
ectoderm being the most common. It remains possible
that some developmental stages of both ectodermal and
breast tissues are influenced by the same gene.
Conventional cytogenetic analysis revealed an apparently
reciprocal balanced translocation of t(1;20)(p34.1;q13.13)
To our knowledge the t(1;20)(p34.1;q13.13) has not been
observed in amastia patients or reported in any cases.
Although this balanced translocation was also detected in
her unaffected mother and sisters, there remained the pos-
sibility that the translocation breakpoint interrupted a
gene responsible for breast development. Other groups
previously identified ALMS1 as the gene responsible for
the autosomal recessive disorder, Alström syndrome,
based on evidence from a balanced chromosomal translo-
cation. In that case, ALMS1 was interrupted by the trans-
location breakpoint, and the other allele had an intragenic
mutation [7]. This stimulated us to determine whether any
genes were interrupted by the breakpoints in our patient.
The FISH study revealed that the breakpoint on chro-
mosome 1 was spanning from intron 7 to intron 11 of
the PTPRF gene. Repetitive sequence elements, includ-
ing Alu, MIR, LINE-L2, and ERVL-MaLRs were found
in the vicinity of the breakpoint region. It is tempting to
speculate that these transposable sequence elements
have promoted this translocation. This situation is simi-
lar to other reported familial germline translocations
which are also localized in regions rich in repetitive
sequences [8].
PTPRF, also known as Leukocyte Common Antigen-
Related molecule (LAR), is a member of the protein tyr-
osine phosphatase (PTP) family. This PTP contains an
extracellular domain of three immunoglubulin-like
domains in combination with eight fibronectin type-III-
like repeats, a single transmembrane domain, and two
intracellular tyrosine phosphatase domains [9]. PTPRF
spans 92 kb, contains 34 exons, with an open reading
frame of 5,724 bp, encoding a 1,907 amino-acid protein.
Ptprf knockout mice exhibit a defect in their mam-
mary glands leading to the inability to deliver milk to
their young [10]. In humans, PTPRF is recognized as a
tumor suppressor gene; somatic mutations were identi-
fied in 9% of breast cancers [11], and some other malig-
nancies showed significantly increased PTPRF
expression [12]. However, germline mutations in PTPRF
have not been identified and the gene has not been
shown to influence organ development in humans.
To substantiate the role of PTPRF in human mam-
mary gland development and to elucidate the mechan-
ism underlying the phenotypic differences between the
proband and her unaffected mother and sister with the
same chromosome translocation, we studied the
expression of the PTPRF in the family’sE B V - t r a n s -
formed lymphoblastoid cell lines. RNA levels in the
mother and elder sister were higher using the 5’ probe
(Figure 3A) compared with the 3’ probe (Figure 3B),
perhaps due to a feedback mechanism to increase tran-
scription of both PTPRF alleles. If that were the case,
t h e nt h ep r e s e n c eo ft h eb r e a k p o i n tw o u l dg i v eal o w e r
level of intact PTPRF RNA when determined by the 3’
probe [13]. As expected, the mother’s PTPRF RNA
level, determined by the 3’ probe, was approximately
half that of the control. However, the reason for the
sister’se l e v a t e dPTPRF RNA level remains to be
elucidated.
We next determined PTPRF protein levels. Western
blot analysis showed that PTPRF expression was nearly
absent in the proband, while her unaffected mother and
older sister had significant (p < 0.05) PTPRF protein
remaining (Figure 3C, D), despite harboring the same
balanced chromosomal translocation.
The proband’sf i n d i n g so fs e v e r e l yd e f i c i e n tPTPRF
RNA and absent PTPRF protein with an interrupted
PTPRF allele on the maternal chromosome, suggested
that our proband’sp a t e r n a lPTPRF allele harbored a
pathogenic mutation. However, sequencing of the gene’s
entire coding regions and its promoter (-654 to + 294)
revealed no obviously pathogenic mutations. Reverse
transcribed - PCR yielded no aberrant splicing patterns,
making a pathogenic intronic mutation or splice-site
mutation unlikely. Measurement of both DNA copy
number and allelic ratios showed no evidence of dele-
tions or duplications (Additional file 1, Figure S1). How-
ever, microsatellite analysis showed that the proband
inherited a paternal chromosome different from that of
her sisters (Additional file 1, Figure S2). The reasons for
significantly decreased PTPRF expression in our patient
despite a lack of pathogenic mutations in the paternal
allele remain to be elucidated.
Conclusions
We have demonstrated that the PTPRF gene is inter-
rupted on chromosome 1 in a woman with bilateral
amastia and a balanced chromosome translocation.
Although a definite pathogenic mutation on the paternal
allele could not be identified, the patient’s PTPRF RNA
is severely deficient and PTPRF protein is barely detect-
able. While the proband’s mother and sisters also harbor
the translocated chromosome, their non-translocated
chromosomes 1 are different from that of the proband
and their PTPRF RNA and protein levels remain at sig-
nificant levels. These findings make PTPRF a prime can-
didate to investigate for its spatial and temporal roles in
human breast development.
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Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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bilateral amastia. Table S1. Review of the reported patients with
bilateral amastia. Table S2. List of FISH probes and their results. Table S3.
List of primers for generation of FISH probes using long-range PCR. Table
S4. List of primers for mutation analysis of PTPRF. Table S5. List of PTPRF
variations found in our patient with syndromic bilateral amastia. Figure
S1. Result of SNP array of the patient. Figure S2. Haplotype analysis of
chromosome 1 of family members
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